Key statistics dashboard for CNS Pharmaceuticals, Inc. (CNSP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Stock Data
| Price | $5.50 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.23 |
| Price / Book | 2.07 |
| P/S | 0.00 |
| P/FCF | -0.60 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 5.86 |
| Quick Ratio | 5.86 |
| Cash Ratio | 5.35 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | -1131.57 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -21.50 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.66 |
| Cash per share | 2.92 |
| FCF per share | -1.97 |
| Tangible Book Value per share | 2.66 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Related companies: CMND · ENSC · GRI · KTTA · NLSP · OGEN · SILO
Explore sector: Healthcare · Biotechnology
More sections of CNSP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks